2010 FIFA World Cup South Africa: Travel health issues and new options for protection against meningococcal disease

Department of Health, United Kingdom, 2009 Centers for Disease Control and Prevention, United States of America National Institute for Communicable Diseases and National Health Laboratory Service, South Africa Commun Dis Surv Bull, 2009, Measles outbreak, 8, 1 2010, Morb Mortal Weekly Rep, 59, 125 Malerczyk C, Nel LH, Gniel D, et al. Rabies in South Africa and the FIFA Soccer World Cup: Travelers’ awareness for an endemic but neglected disease. Human Vaccines, 6(5), in press. Health Department, Republic of South Africa, 2005 2007 2008 2009, Meningococcal disease update, Commun Dis Commun, 8, 5 Commun Dis Surv Bull, 2008, Meningococcal disease update, 8, 4 Koch, 1994, Meningococcal disease in travelers: vaccination recommendations, J Travel Med, 1, 4, 10.1111/j.1708-8305.1994.tb00548.x Granoff, 2008, Meningococcal vaccines, 399 European Centre for Disease Prevention and Control, 2008 Wilder-Smith, 2008, Meningococcal disease: risk for international travellers and vaccine strategies, Travel Med Infect Dis, 6, 182, 10.1016/j.tmaid.2007.10.002 Wilder-Smith, 2009, Meningococcal vaccines: a neglected topic in travel medicine?, Expert Rev Vaccines, 8, 1343, 10.1586/erv.09.102 Booy, 2009, Influenza and meningococcal disease: lessons for travellers and government from two epidemic diseases, Travel Med Infect Dis, 7, 253, 10.1016/j.tmaid.2008.09.001 Reintjes, 2002, Detection and response to a meningococcal disease outbreak following a youth football tournament with teams from four European countries, Int J Hyg Health, 205, 291, 10.1078/1438-4639-00156 Pace, 2009, DMenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for prevention of meningococcal infection, Curr Opin Mol Ther, 11, 692 Reisinger KS, Black S, Stoddard JJ Optimizing protection against meningococcal disease. Clin Pediatr, doi:10.1177/0009922809354327. Pace, 2009, Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy, Expert Rev Vaccines, 8, 529, 10.1586/erv.09.18 Granoff, 2007, Reconsideration of the use of meningococcal polysaccharide vaccine, Pediatr Infect Dis J, 26, 716, 10.1097/INF.0b013e3180cc2c25 Bröker, 2010, Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine, Travel Med Infect Dis, 8, 47, 10.1016/j.tmaid.2009.12.001 Maiden, 2008, Impact of meningococal serogroup C conjugate vaccines on carriage and herd immunity, J Infect Dis, 197, 737, 10.1086/527401 Bilukha, 2005, Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP), MMWR Recomm Rep, 54, 1 Centers for Disease Control and Prevention, United States of America, 2010, Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use – advisory committee on immunization practices (ACIP), MMWR, 2010, 273 European medicines agency pre-authorisation evaluation of medicines for human use committee for medicinal products for human use. Summary of positive opinion for Menveo common name: meningococcal Group A, C, W-135 and Y Coniugate Vaccine Doc. Ref. EMA/CHMP/796967/2009. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), 2008, Report from the advisory committee on immunization practices (ACIP): decision not to recommend routine vaccination of all children aged 2–10 years with quadrivalent meningococcal conjugate vaccine (MCV4), MMWR Morbid Mortal Wkly Rep, 57, 462 Department of Health, United Kingdom, 2009